NASDAQ:ONTXOnconova Therapeutics Stock Price, Forecast & News

Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONTX stock has increased by 61.3% and is now trading at $0.5805. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Onconova Therapeutics.

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Onconova Therapeutics.

Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.10 million. Onconova Therapeutics had a negative net margin of 876.56% and a negative return on equity of 340.18%. View Onconova Therapeutics' earnings history.

Shares of Onconova Therapeutics reverse split on the morning of Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 analysts have issued 1 year target prices for Onconova Therapeutics' stock. Their forecasts range from $1.25 to $1.30. On average, they expect Onconova Therapeutics' share price to reach $1.28 in the next twelve months. This suggests a possible upside of 119.6% from the stock's current price. View analysts' price targets for Onconova Therapeutics.

Media stories about ONTX stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Onconova Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Onconova Therapeutics.

Some companies that are related to Onconova Therapeutics include Kamada (KMDA), Albireo Pharma (ALBO), Spectrum Pharmaceuticals (SPPI), Organogenesis (ORGO), Tocagen (TOCA), Calithera Biosciences (CALA), Progenics Pharmaceuticals (PGNX), Wave Life Sciences (WVE), Axovant Sciences (AXON), MEI Pharma (MEIP), MannKind (MNKD), Affimed (AFMD), ANI Pharmaceuticals (ANIP), Magenta Therapeutics (MGTA) and Neptune Wellness Solutions (NEPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Opko Health (OPK), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and Agile Therapeutics (AGRX).

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.06%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, Michael B Hoffman, Steven M Fruchtman and Tyndall Capital Partners L P. View institutional ownership trends for Onconova Therapeutics.

ONTX stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman. View insider buying and selling activity for Onconova Therapeutics.

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONTX stock can currently be purchased for approximately $0.58.

Onconova Therapeutics has a market capitalization of $97.91 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

The official website for Onconova Therapeutics is www.onconova.com.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]